UBS Group AG Sells 161,513 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT

UBS Group AG decreased its position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 46.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 188,651 shares of the company’s stock after selling 161,513 shares during the period. UBS Group AG owned about 0.23% of Eyepoint Pharmaceuticals worth $3,447,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of EYPT. State of Alaska Department of Revenue acquired a new stake in shares of Eyepoint Pharmaceuticals in the third quarter valued at approximately $50,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after purchasing an additional 1,358 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Eyepoint Pharmaceuticals in the 3rd quarter valued at $76,000. Tower Research Capital LLC TRC lifted its position in Eyepoint Pharmaceuticals by 218.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after acquiring an additional 5,967 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after acquiring an additional 1,177 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Insider Buying and Selling

In related news, insider Ramiro Ribeiro sold 2,437 shares of the company’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 4.46% of the company’s stock.

Analyst Ratings Changes

EYPT has been the topic of several recent research reports. Chardan Capital lifted their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Citigroup lifted their price target on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, March 9th. HC Wainwright lifted their price target on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Finally, Royal Bank Of Canada lowered their price target on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Eyepoint Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $31.80.

Eyepoint Pharmaceuticals Price Performance

Eyepoint Pharmaceuticals stock opened at $12.93 on Monday. The firm has a market capitalization of $1.08 billion, a PE ratio of -3.69 and a beta of 1.76. The company’s 50-day moving average is $13.46 and its 200-day moving average is $14.68. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.20). The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million. Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%. As a group, analysts expect that Eyepoint Pharmaceuticals, Inc. will post -3.16 EPS for the current year.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.